Search Results for "Infection"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Infection. Results 281 to 290 of 842 total matches.
A Once-Daily Combination Tablet (Atripla) for HIV
The Medical Letter on Drugs and Therapeutics • Sep 25, 2006 (Issue 1244)
) is the first oncedaily, single-tablet combination of 3 antiretroviral drugs
for treatment of HIV infection ...
Atripla (Gilead/Bristol-Myers Squibb) is the first once daily, single-tablet combination of 3 antiretroviral drugs for treatment of HIV infection. Each tablet contains 600 mg of the non-nucleoside reverse transcriptase inhibitor (NNRTI) efavirenz (Sustiva), 200 mg of the nucleoside reverse transcriptase inhibitor (NRTI) emtricitabine (Emtriva), and 300 mg of the nucleotide reverse transcriptase inhibitor (NRTI) tenofovir DF (Viread). These drugs have been recommended for use together, if resistance testing confirms susceptibility, as an initial regimen of choice for treatment-na∩ve...
Canagliflozin (Invokana) for Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • May 13, 2013 (Issue 1416)
Weight loss, low risk of hypo- Genital mycotic infections, urinary 263.00
glycemia tract infection ...
Canagliflozin (kan" a gli floe' zin; Invokana – Janssen),
a sodium-glucose co-transporter 2 (SGLT2) inhibitor,
has been approved by the FDA for oral treatment of
type 2 diabetes.
Drugs for Pneumonia
Treatment Guidelines from The Medical Letter • Sep 01, 2003 (Issue 13)
on the most likely pathogens causing the
infection and local antimicrobial resistance patterns.
Factors ...
The choice of drugs for treatment of pneumonia depends on the most likely pathogens causing the infection and local antimicrobial resistance patterns. Factors such as severity of illness, presence of co-morbid conditions and whether the infection is community or hospital-acquired also need to be considered.
Lefamulin (Xenleta) for Community-Acquired Bacterial Pneumonia
The Medical Letter on Drugs and Therapeutics • Sep 23, 2019 (Issue 1581)
are limited. Lefamulin is also
active in vitro against pathogens that cause sexually
transmitted infections ...
Lefamulin (Xenleta – Nabriva), a semisynthetic
pleuromutilin antibiotic, has been approved by the
FDA for IV and oral treatment of community-acquired
bacterial pneumonia (CABP) in adults. It is the first
systemic pleuromutilin antibiotic to be approved in the
US; retapamulin (Altabax), a 1% topical ointment for
treatment of impetigo, was approved in 2007.
Booster Doses of COVID-19 Vaccines
The Medical Letter on Drugs and Therapeutics • Nov 29, 2021 (Issue 1638)
likely
to be infected with SARS-CoV-2 than those who
were not vaccinated, but the relative risk ...
The FDA has expanded the Emergency Use Authorizations
(EUAs) for the mRNA-based COVID-19 vaccines
manufactured by Pfizer/BioNTech (Comirnaty) and
Moderna (Spikevax) and the adenovirus-based vaccine
manufactured by Johnson & Johnson/Janssen to
include administration of a booster dose in select
populations after primary immunization with either the
same COVID-19 vaccine or a different one.
In Brief: Recommendation for Earlier Antibiotic Prophylaxis for Cesarean Delivery
The Medical Letter on Drugs and Therapeutics • Oct 04, 2010 (Issue 1348)
of
endometritis and wound infection with preoperative
antibiotic administration compared to administration
post ...
The American Congress of Obstetricians and Gynecologists (ACOG) has announced a new recommendation for antibiotic prophylaxis during cesarean delivery.1 Currently most women receive a single dose of prophylactic antibiotics after the umbilical cord has been clamped to prevent antibiotics from crossing over to the newborn. The new recommendation is for women giving birth by cesarean section to routinely receive antibiotics within one hour before the start of surgery. In the case of an emergency cesarean delivery, prophylaxis should be started as soon as possible.Recent studies have found a...
Mumps Outbreak
The Medical Letter on Drugs and Therapeutics • Mar 17, 2014 (Issue 1438)
in older people could
be due to a lower level of exposure or superior immunity
from natural infection ...
An outbreak of mumps has occurred among students at
Fordham University in New York. All of those who developed
mumps had been vaccinated against the disease.
In Brief: A New Formulation of Posaconazole (Noxafil)
The Medical Letter on Drugs and Therapeutics • Feb 02, 2015 (Issue 1461)
drug posaconazole (Noxafil - Merck) for
prophylaxis of Aspergillus and Candida infections
in adults ...
The FDA has approved an IV formulation of the antifungal drug posaconazole (Noxafil - Merck) for prophylaxis of Aspergillus and Candida infections in adults at high risk for these infections, such as those with prolonged neutropenia. Posaconazole is also available as delayed-release tablets and an oral suspension.With activity against Aspergillus and Candida, posaconazole has an antifungal spectrum similar to that of voriconazole (Vfend, and generics), but unlike voriconazole it is also active against many species of Mucorales (formerly called Zygomycetes), such as Mucor and Rhizopus....
Atovaquone for Pneumocystis Carinii Pneumonia
The Medical Letter on Drugs and Therapeutics • Apr 02, 1993 (Issue 893)
opportunistic infection and frequent cause of death in patients with AIDS.
STANDARD THERAPY — Trimethoprim ...
Atovaquone (Mepron - Burroughs Wellcome), a hydroxynaphthoquinone, was recently approved by the US Food and Drug Administration (FDA) for oral treatment of mild to moderate Pneumocystis carinii pneumonia (PCP) in patients who cannot tolerate trimethoprim-sulfamethoxazole (Septra, Bactrim, and others). PCP is a common opportunistic infection and frequent cause of death in patients with AIDS.
Aerosolized Deoxyribonuclease for Cystic Fibrosis
The Medical Letter on Drugs and Therapeutics • Apr 15, 1994 (Issue 920)
in the mucus-obstructed airways of patients
with cystic fibrosis leads to recurrent pulmonary infections ...
Recombinant human deoxyribonuclease I (rhDNase; dornase alfa; Pulmozyme - Genentech), an enzyme that hydrolyzes extracellular DNA, is now available as a purified solution to decrease the viscosity of sputum in patients with cystic fibrosis. It requires a nebulizer to produce an aerosol mist for inhalation.